Funded Project Details - FY2021
|Title:|| A novel treatment for bone fracture repair|
||San Francisco, CA
|Congressional District Code:
||Biomedical Laboratory R&D
|| October 2017 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Bone fractures pose a significant problem for veterans who suffered from traumatic injury in the line of military duty or from prevalent osteoporotic diseases as a civilian. Intermittent (or daily) administration of parathyroid hormone (PTH) is the only FDA-approved pharmaceutics that produces osteoanabolism to treat osteoporosis. The osteoanabolic action of PTH is based on the ability of the hormone to alter systemic and local factors that promote osteoblast (OB) activity before its stimulation...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.